Tharimmune, Inc. Prices $55 Million Offering to Support Canton Network
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Offering Size: Tharimmune, Inc. announced the pricing of 1,800,000 shares at $2.92 each, raising a total of $55 million, with the offering expected to close on January 21, 2026, aimed at funding the company's Canton Network-centric digital asset strategy expansion.
- Strategic Importance: This financing will provide Tharimmune with additional growth capital to support innovation in the digitization of traditional financial markets, while enhancing its competitive position in the blockchain sector and facilitating further development in biotech research.
- Market Reaction: As the first publicly traded company leveraging Canton Coin, Tharimmune's initiative may attract increased investor interest in its blockchain technology applications, potentially enhancing the company's image and valuation in the capital markets.
- Underwriting Arrangement: Clear Street is acting as the sole bookrunner for this offering, ensuring a smooth financing process and providing necessary support and information to investors, thereby boosting market confidence in the transaction.
Analyst Views on THAR
About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
